ɐ klˈɪnɪkəl stˈʌdi ˈænɐlˌaɪzɪŋ ðɪ ɪfˈɪʃənsi ʌvðə dɹˈʌɡ fˈaʊnd ðæt lˈæɹətɹˌɛktɪnˌɪb wʌz ɐn ɪfˈɛktɪv ˈæntaɪ tˈuːmɚ tɹˈiːtmənt, ænd wˈɜːkt ɪfˈɪʃəntli ɹᵻɡˈɑːɹdləs ʌv ˈeɪdʒ ʌvðə pˈeɪʃənt ɔːɹ tˈuːmɚ tˈaɪp; ɐdˈɪʃənəli, ðə dɹˈʌɡ dɪdnˌɑːt hæv lˈɔŋ lˈæstɪŋ sˈaɪd ɪfˈɛkts, hˈaɪlaɪɾɪŋ ðə bˌɛnɪfˈɪʃəl jˈuːs ʌv ðɪs dɹˈʌɡ ɪn tɹˈiːɾɪŋ tˌiːˌɑːɹkˈeɪ fjˈuːʒənz.
A clinical study analyzing the efficiency of the drug found that Larotrectinib was an effective anti tumor treatment, and worked efficiently regardless of age of the patient or tumor type; additionally, the drug did not have long lasting side effects, highlighting the beneficial use of this drug in treating Trk fusions.